CVC  Pfizer Strategic Investments Group

http://www.pfizer.com/partnering/areas_of_int erest/venture_investments.jsp





     Office Locations:

235 East 42nd Street
New York, NY 10017
Phone: 212-733-7034
Fax: 212-883-4873

 

Stages:

  • Expansion
  • Growth


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Pfizer Strategic Investments Group is part of Pfizer's goal to fund innovation in pharmaceutical and animal health products by working with partners to identify, develop and commercialize products that will bring value to Pfizer's companies and improve the lives of patients. Pfizer has been successful in attracting and developing licensing and alliance opportunities for more than two decades. More recently, Pfizer has added a venture investments group that provides funding to existing or new companies that can advance Pfizer's commercial interests. Pfizer focuses on the following three types of opportunities: Marketed drugs and investigational compounds to fill gaps in the existing portfolio and pipeline; Innovative approaches to delivery systems, product combinations, and diagnostics, which may have the potential to better match patients with therapies; and Adjacent or complementary healthcare business outside pharmaceuticals, where Pfizer believes there are revenue generating opportunities. With a $50M annual budget for private investments, PVI may invest up to $10M per round in selected companies in any stage of development, with a strong focus on growth stage opportunities. The firm's typical investment ranges between $500,000 and $5 million. Pfizer specializes in middle and late stage investments based in or operating in the U.S.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Barbara Dalton PhD Vice President
    Bill Burkoth Senior Director
    Elaine Jones PhD Executive Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      10/18/2017


      Blade Therapeutics


      CA


      $45,000,000


      Series B


      07/26/2017


      Complexa


      PA


      $62,000,000


      Series C


      07/24/2017


      Effector Therapeutics


      CA


      $38,600,000


      Series C


      06/06/2017


      Neuronetics


      PA


      $15,000,000


      Series G


      02/27/2017


      Arrakis Therapeutics


      MA


      $38,000,000


      Series A


      02/17/2017


      Rhythm


      MA


      $41,000,000


      Mezzanine


     

    Portfolio companies include:


      Ablexis Consortium
        web link


      Aquinox
        web link


      Arrakis Therapeutics
        web link


      Aureon Laboratories
        web link


      Autifony
        web link


      Avid Radiopharmaceuticals
        web link


      Aviir
        web link


      Biodesy
        web link


      Blade Therapeutics
        web link


      Celladon
        web link


      Circle Pharma
        web link


      Clovis Oncology
        web link


      Complexa
        web link


      CytomX
        web link


      DVS Sciences
        web link


      Effector Therapeutics
        web link


      Entelos
        web link


      Epic Sciences
        web link


      Flexion Therapeutics
        web link


      Genomic Health
        web link


      HandyLab
        web link


      HD Biosciences
        web link


      Lodo Therapeutics
        web link


      M2S
        web link


      Mersana Therapeutics
        web link


      Merus
        web link


      MIRNA
        web link


      Neuronetics
        web link


      NextCure


      Nimbus Therapeutics
        web link


      Nodality
        web link


      Quartet Medicine
        web link


      Rhythm
        web link


      Second Genome
        web link


      TetraLogic
        web link


      Vtesse
        web link


     

    Recent News: